Vectus Biosystems Share Price and Company Fundamentals
Last traded: Today at 4:45 AM
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. The company was incorporated in 2005 and is based in Rosebery, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
-
Beta
0.48
Market cap
$6.14M
Enterprise value
$6.08M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.vectusbiosystems.com.au |
| Mailing address | 26-34 Dunning Avenue Unit 5, Ground Floor Rosebery NSW 2018 Australia |
| Phone / Fax | 61 2 8344 1300 / 61 2 9697 0944 |
Dividends
More: Vectus Biosystems Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Vectus Biosystems paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.VBS dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Vectus Biosystems.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Ivan Rajkovic Ph.D. | Interim Chief Technology Officer | ||
| Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin | Company Secretary | ||
| Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D. | Consultant |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-800.96%
Return on assets
-75.73%
Return on equity
-289.05%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Vectus Biosystems is 6.14M and its enterprise value is 6.08M. The enterprise value to revenue ratio of VBS is 12.71. The enterprise value to EBITDA ratio of VBS is -3.60.
The VBS's stocks Beta value is 0.48 making it 52% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Vectus Biosystems (VBS)
Vectus Biosystems (ASX:VBS) Frequently Asked Questions
1. What is Vectus Biosystems's Stock Symbol?
Vectus Biosystems trades on ASX under the ticker symbol "VBS".
2. What is Vectus Biosystems's stock price today?
One share of VBS stock can currently be purchased for approximately $0.115.
3. How can I contact Vectus Biosystems?
Vectus Biosystems's mailing address is 26-34 Dunning Avenue Unit 5, Ground Floor Rosebery NSW 2018 Australia. The company can be reached via phone at 61 2 8344 1300.
4. What is Vectus Biosystems's official website?
The official website of Vectus Biosystems is https://www.vectusbiosystems.com.au.